Norbert is an Independent consultant and teaches at the Clinica Oculistica, University-Hospital of Padova. He was previously in private practice at at Augencentrum Köln in Cologne, Germany.
He was part of the study team which undertook the pivotal FDA study for iTrack 250A, leading to its clearance in 2008.
He first introduced ab interno canaloplasty into Germany in 2014. Along with Simon Ondrejka, MD, he has published 6-year canaloplasty data with iTrack 250A in 2024.
In 2022 Norbert was the first adopter of iTrack Advance in Germany. He joined the CATALYST Study as Coordinating Investigator in 2022.
